

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY

December 1, 2020

DEPARTMENT MEMORANDUM

No. 2020 - _____

TO:

DIRECTORS OF THE DEPARTMENT OF HEALTH
DEVELOPMENT - ILOCOS,

CENTERS FOR HEALTH DEVELOPMENT - ILOCOS, CENTRAL LUZON, METRO MANILA, CALABARZON, BICOL, WESTERN VISAYAS, CENTRAL VISAYAS, ZAMBOANGA PENINSULA, NORTHERN MINDANAO, AND

DAVAO

SUBJECT:

Conduct of Preparatory Activities for the Implementation of the

"Pilot Study to Evaluate the Effectiveness and Safety of the

Bedaquiline-Pretomanid-Linezolid (BPaL) treatment regimen in

the Philippines"

The National Tuberculosis Control Program (NTP) of the Department of Health (DOH), in collaboration with the Lung Center of the Philippines – National Center for Pulmonary Research (LCP-NCPR), KNCV Tuberculosis Foundation, International Tuberculosis Research Center, Korea, and TB Alliance, will embark on an operational research entitled "Pilot study to test the effectiveness and safety of the Bedaquiline, Pretomanid, Linezolid (BPaL) treatment regimen in the Philippines". The proposed study primarily aims to estimate the effectiveness of the BPaL regimen by assessing the end of treatment outcome among patients treated with the regimen, and to estimate the safety of the BPaL regimen by determining the rates of serious adverse events. This is an initiative to ensure successful treatment outcome of patients with extensively drug-resistant tuberculosis, treatment-intolerant or non-responsive multidrug-resistant tuberculosis.

The operational research (OR) will enroll 100 patients for 2 years in the following

twelve (12) health facilities providing drug-resistant TB (DR-TB) services:

(MELVE	12) health facilities providing drug resistant 1B (Bit 1B) services.
Region	Facility
NCR	Lung Center of the Philippines, Quezon City
	Dr. Jose N. Rodriguez Memorial Hospital, Caloocan City
1	Ilocos Training and Regional Medical Center, La Union
	Region I Medical Center, Dagupan City
3	Jose B. Lingad Memorial General Hospital, Pampanga
4	Batangas Medical Center, Batangas
5	Sorsogon Medical Mission Group Hospital and Health Services Cooperative, Sorsogon
6	Western Visayas Medical Center, Iloilo City
7	Eversley Childs Sanitarium and General Hospital, Mandaue City
9	Zamboanga City Medical Center, Zamboanga City
10	Xavier University - Community Health Care Center, Cagayan de Oro City
11	Southern Philippines Medical Center, Davao City

These facilities were selected based on the following: 1) has been implementing the programmatic management of drug-resistant TB (PMDT) for one (1) year or more; 2) has a strategic location providing access to other referring facilities; 3) with access to private and public facilities for the identification and management of adverse events and comorbidities; 4) has access to diagnostic and monitoring laboratories; 5) has >30 patients with DR-TB

enrolled in 2019; and 6) has a designated physician trained in PMDT.

Prior to the implementation of the OR, the following preparatory activities shall be conducted:

- 1) **needs assessment** of the study sites and its partner TB laboratories (rapid TB diagnostic, TB culture, drug susceptibility testing and line probe assay laboratories) by LCP-NCPR research team and the National TB Reference Laboratory (NTRL) Research Institute for Tropical Medicine (refer to Annex 1. List of Proposed Study Sites and Its Partner TB Laboratories),
- 2) orientation on the study protocol of key stakeholders including CHD NTP Coordinators and study site staff on December 10, 2020 by NTP, LCP-NCPR and partners, and
- 3) following the orientation, solicitation of a letter of commitment and support from the heads of the institution/hospital and STC to implement the study by the CHD, through the NTP Coordinators.

Relative to this, identified health facilities providing DR-TB services including its partner TB laboratories are requested to participate in the said preparatory activities and in this landmark study. Rest assured that the conduct of the study will be supported by the NTP Management Office, LCP-NCPR, and NTP partners.

Further, the study protocol will undergo technical and ethical review and approval prior to the implementation of the OR. Once approved, a Department Memorandum will be issued to signal the start of the study.

For information, compliance, and dissemination to all concerned.

By Authority of the Secretary of Health

MYRNA C. CABOTAJE, MD, MPH, CESO III

Undersecretary of Health Public Health Services Team

Annex 1. List of Proposed Study Sites and Its Partner TB Laboratories

Region	Health Facility Providing DR-TB	Rapid TB Diagnostic	TB Culture	DST	LPA
0		Laboratory (RTDL)	Laboratory	Laboratory	Laboratory
	Lung Center of the Philippines (LCP)	LCP	LCP	NTRL	NTRL
NCR	Dr. Jose N. Rodriguez Memorial Hospital (DJNRMH)	DJNRMH	LCP	NTRL	NTRL
	Hocos Training and Regional Medical	La Union Medical Center	Dagupan Doctors	NTRL	NTRL
	Center (ITRMC)	(LUMC)	Villaflor Memorial		
Н			Hospital (DDVIMH)		
	Region I Medical Center (R1MC)	Pangasinan Provincial Hospital (PPH)	ррумн	NTRL	NTRL
目	Jose B. Lingad Memorial General Hospital (JBLMGH)	JBLMGH	Central Luzon CHD TBC Laboratory	NTRL	NTRL
IV A	Batangas Medical Center (BatMC)	BatMC	Philippine Tuberculosis Society Inc. (PTSI-QI)	PTSI-QI	NTRL
	Sorsogon Medical Mission Group	Only patients screened in	SMMGHIHSC	NTRL	NTRL
	Hospital and Health Services	the SMMGHHSC; the rest			
>	(SMMGHHSC)	of the zoned specimens are			
		temporarily routed to			
		Gubat and Pilar RTDLs			
VI	Western Visayas Medical Center (WVMC)	WVMC	WVMC	WVMC	NTRL
VIII	Eversley Child Sanitarium (ECS)	ECS	PTSI-QI	PTSI-QI	NTRL
	Zamboanga City Medical Center	ZCMC	ZCMC	Davao TB	NTRL
X	(ZCMC)			Reference	
:				Laboratory (DTRL)	
×	Xavier University-Community Health Care Center (XU-CHCC)	XU-CHCC	CDO Polymedic Plaza (CDOPMP)	DTRL	NTRL
IX	Southern Philippines Medical Center (SPMC)	SPMC	DTRL	DTRL	NTRL